Mason Wells
Mason Wells is a Wisconsin-based private equity firm founded in 1998 that specializes in mid-market investments within the biotechnology, medical devices, and life sciences sectors. The firm also invests in consumer packaged goods, engineered products and services, outsourced business services, and packaging materials. With a revenue range between $25 million and $300 million, Mason Wells aims to support founders, family owners, and managers during ownership transitions, helping businesses realize their potential while maintaining their legacy and culture. Its portfolio includes companies such as A and R Logistics, AWT Labels and Packaging, CE Power Solutions, Eddy Packing, and Aquion.
L.B. White Company, Inc. is a global manufacturer based in Onalaska, Wisconsin, specializing in a range of heating products including forced air heaters, radiant heaters, brooders, tube heaters, handheld gas torches, convection heaters, and portable heaters. Established in 1952, the company focuses on providing tailored heating solutions for various industries such as agriculture, horticulture, construction, and special event rentals. Its product line includes heaters specifically designed for swine, poultry, greenhouses, tents, and construction sites. L.B. White distributes its products through a network of dealers across North America, Europe, Asia, and South America, and maintains additional operations in Russia and China. The company is committed to delivering fuel-efficient and reliable heating systems to meet the unique requirements of its diverse clientele.
King Juice is a manufacturer and marketer of the Calypso brand of lemonade drinks and a leading co-manufacturer of non-alcoholic beverages. Calypso, the originator of the Flavored Lemonade category, has evolved from four Lemonade blends into twenty unique Lemonade, Limeade and Teamonade® combinations over the past nineteen years.
MGS Mfg. Group specializes in the manufacturing of injection molded plastic components, catering to a diverse clientele that includes original equipment manufacturers and brand owners across various industries such as healthcare, automotive, electronics, and consumer goods. The company offers a comprehensive range of services, including engineering and design-for-manufacture, mold making, sampling and development, as well as value-added contract manufacturing operations. MGS Mfg. Group is recognized for its high-precision technical plastic products and multishot technologies, delivering solutions that enable automation and enhance efficiency in manufacturing processes. Its extensive experience in tooling, molding, and equipment systems allows MGS to serve a broad spectrum of applications, part geometries, and resins, with a strong presence in North America and Europe.
Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of renal diseases, osteoporosis, skin diseases, and other targets. It focuses on vitamin D analogs and other compounds to develop selected therapies through early phases of the drug development process. The company’s product includes DP001 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis. It also develops DP006 for the treatment of acne. The company was founded in 1999 and is based in Madison, Wisconsin.
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. "Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture. The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production.